|
1
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
33.60
|
|
2
|
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
|
J Clin Oncol
|
2005
|
6.90
|
|
3
|
Benign breast disease and the risk of breast cancer.
|
N Engl J Med
|
2005
|
6.84
|
|
4
|
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
|
J Clin Oncol
|
2006
|
4.55
|
|
5
|
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
|
Breast Cancer Res Treat
|
2006
|
4.35
|
|
6
|
Stratification of breast cancer risk in women with atypia: a Mayo cohort study.
|
J Clin Oncol
|
2007
|
2.58
|
|
7
|
Centrosome amplification and the development of cancer.
|
Oncogene
|
2002
|
2.51
|
|
8
|
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
|
J Clin Oncol
|
2010
|
2.49
|
|
9
|
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
|
Clin Cancer Res
|
2006
|
2.27
|
|
10
|
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
|
J Clin Oncol
|
2013
|
2.15
|
|
11
|
Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
|
Gynecol Oncol
|
2009
|
1.82
|
|
12
|
Folate receptor overexpression is associated with poor outcome in breast cancer.
|
Int J Cancer
|
2007
|
1.65
|
|
13
|
Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness.
|
Breast Cancer Res Treat
|
2002
|
1.58
|
|
14
|
Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats.
|
Proc Natl Acad Sci U S A
|
2004
|
1.50
|
|
15
|
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
|
J Clin Oncol
|
2008
|
1.41
|
|
16
|
Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer.
|
J Biol Chem
|
2007
|
1.39
|
|
17
|
Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays.
|
BMC Genomics
|
2011
|
1.35
|
|
18
|
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
|
Breast Cancer Res Treat
|
2013
|
1.34
|
|
19
|
Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
|
Clin Cancer Res
|
2005
|
1.26
|
|
20
|
Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy.
|
J Biol Chem
|
2004
|
1.23
|
|
21
|
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.
|
J Natl Cancer Inst
|
2008
|
1.22
|
|
22
|
Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer.
|
Breast Cancer Res
|
2012
|
1.21
|
|
23
|
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.
|
Lancet Oncol
|
2009
|
1.21
|
|
24
|
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
|
J Clin Oncol
|
2011
|
1.21
|
|
25
|
Cisplatin abrogates the geldanamycin-induced heat shock response.
|
Mol Cancer Ther
|
2008
|
1.10
|
|
26
|
Centrosome amplification and the origin of chromosomal instability in breast cancer.
|
J Mammary Gland Biol Neoplasia
|
2004
|
1.08
|
|
27
|
Chronic exposure to lead chromate causes centrosome abnormalities and aneuploidy in human lung cells.
|
Cancer Res
|
2006
|
1.08
|
|
28
|
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
|
Cancer
|
2013
|
1.06
|
|
29
|
Aurora A, centrosome structure, and the centrosome cycle.
|
Environ Mol Mutagen
|
2009
|
1.05
|
|
30
|
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
|
Breast Cancer Res
|
2011
|
1.05
|
|
31
|
Tissue composition of mammographically dense and non-dense breast tissue.
|
Breast Cancer Res Treat
|
2011
|
1.05
|
|
32
|
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
|
Mol Cancer Ther
|
2008
|
1.01
|
|
33
|
Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.00
|
|
34
|
Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.
|
Cancer Res
|
2008
|
0.98
|
|
35
|
Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia.
|
Cancer Res
|
2007
|
0.97
|
|
36
|
The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate.
|
Mol Cancer Res
|
2004
|
0.96
|
|
37
|
Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients.
|
Lung Cancer
|
2013
|
0.96
|
|
38
|
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
|
Clin Cancer Res
|
2008
|
0.95
|
|
39
|
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.
|
Clin Cancer Res
|
2011
|
0.95
|
|
40
|
Aromatase immunoreactivity is increased in mammographically dense regions of the breast.
|
Breast Cancer Res Treat
|
2010
|
0.94
|
|
41
|
Quantifying insulin receptor isoform expression in FFPE breast tumors.
|
Growth Horm IGF Res
|
2012
|
0.93
|
|
42
|
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
|
Sci Transl Med
|
2013
|
0.92
|
|
43
|
Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.
|
PLoS One
|
2013
|
0.91
|
|
44
|
Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.
|
J Cell Biochem
|
2012
|
0.90
|
|
45
|
The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.
|
J Soc Gynecol Investig
|
2006
|
0.87
|
|
46
|
Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas.
|
Mod Pathol
|
2004
|
0.87
|
|
47
|
Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.
|
J Clin Invest
|
2009
|
0.85
|
|
48
|
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.
|
BMC Med Genomics
|
2010
|
0.84
|
|
49
|
Control of centrin stability by Aurora A.
|
PLoS One
|
2011
|
0.84
|
|
50
|
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
|
BMC Cancer
|
2014
|
0.84
|
|
51
|
Applications of cellular systems biology in breast cancer patient stratification and diagnostics.
|
Comb Chem High Throughput Screen
|
2009
|
0.83
|
|
52
|
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
|
Clin Cancer Res
|
2013
|
0.82
|
|
53
|
North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.
|
Clin Breast Cancer
|
2012
|
0.82
|
|
54
|
Specific overexpression of cyclin E·CDK2 in early preinvasive and primary breast tumors in female ACI rats induced by estrogen.
|
Horm Cancer
|
2010
|
0.81
|
|
55
|
Expression of selected Aurora A kinase substrates in solely estrogen-induced ectopic uterine stem cell tumors in the Syrian hamster kidney.
|
Adv Exp Med Biol
|
2008
|
0.77
|
|
56
|
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
|
Bone
|
2010
|
0.75
|